NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

InterCure Ltd. (INCR) Stock Analysis

InterCure Ltd. (INCR) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INCR

$4.42

−$0.01 (−0.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INCR with… →

INCR Key Statistics

As of Oct 21, 2026
Trading
Open
$4.60
Previous Close
$4.43
Day's Range
4.42–4.62
52-Week Range
3.40–7.60
Volume
4.93K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.64
Valuation
Market Cap
$66.32M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.95
Financials (FY)
Revenue (FY)
$270.20M+13.13%
Net Income (FY)
−$35.71M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.00M
1-Year Return
−40.67%
Dividend and dates
Avg Volume
22.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INCR closed at $4.42, −40.67% over 1 year.

InterCure Ltd. (INCR) has a market capitalization of $66.32M.

In fiscal 2025, INCR reported revenue of $270.20M.

INCR Stock Return by Calendar Year

InterCure Ltd. (INCR) return since Jan 2019: what $10,000 became

1 year
$10,000 $5,933
−40.67%
5 years
$10,000 $1,314
−86.86%
Since Jan 2019
$10,000 $3,522
−64.78%

If you had invested $10,000 in InterCure Ltd. (INCR) at the close on January 28, 2019, the earliest close on record here, it would have been worth $3,522 at the close on October 21, 2026: −64.78% in total, −12.63% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.86%
2025−42.77%
2024+23.26%
2023−60.91%
2022−49.07%
2021+398.46%
2020+4.84%
2019−50.60%

As of October 21, 2026.

INCR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$270.20M−$35.71M−13.2%
2024$238.85M−$67.80M−28.4%
2023$355.55M−$61.96M−17.4%
2022$388.68M$44.82M11.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$270.20M$33.18M$6.73M−$35.71M−13.2%
2024$238.85M$30.23M−$45.06M−$67.80M−28.4%
2023$355.55M$105.10M$37.59M−$61.96M−17.4%
2022$388.68M$155.08M$41.20M$44.82M11.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INCR Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricINCRDrug Manufacturers - Specialty & Generic medianvs median
Profit margin−13.22%−8.14%5.1 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

InterCure Ltd. (INCR) is capitalised at $66.32M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 285 employees.

INCR last closed at $4.42 on October 21, 2026. That is −$0.01 (−0.23%) against the previous close. Over the past 52 weeks the price has ranged from $3.40 to $7.60. The latest close sits 30% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $270.20M. Against the prior fiscal year total of $238.85M, that is a change of +13.13%. The same year closed with a net loss of $35.71M. The reported profit margin is −13.22%. That is 5.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.95.

Across the 4 fiscal years on file, revenue moves from $388.68M in 2022 to $270.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.64. Annualized volatility over the trailing 7 years is 178.51%. Over the trailing twelve months the total return is −40.67%. Measured over 5 years, that is −33.37% a year compounded.

Growth & Income

No dividend is on file for INCR.

So far in 2026 the total return is −2.86%. The strongest complete calendar year on file is 2021 at +398.46%; the weakest is 2023 at −60.91%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

InterCure Ltd. (INCR) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
InterCure Ltd. INCR $66.32M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. InterCure Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About InterCure Ltd.

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Visit website →